Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the <scp>COMPASS</scp> randomized controlled trial

Takihata, Masahiro; Nakamura, Akinobu; Tajima, Kazuki; Inazumi, Takaharu; Komatsu, Yumiko; Tamura, Hideki; Yamazaki, Shunsuke; Kondo, Yoshinobu; Yamada, Masayo; Kimura, Masashi; Terauchi, Yasuo

doi:10.1111/dom.12055

Cited by 30 publications

(44 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 1332 patients enrolled in this study, 826 patients have been taking sitagliptin for 24 months and HbA1c <7.0% (<53 mmol/mol) was achieved in 387 patients (46%). A significant increase in Cr, albeit within normal limits, have been reported in clinical studies in Japan [3,5]. On the other hand, elevation of Cr level was not reported in any of the previous studies carried out to evaluate the influence of sitagliptin on the renal function, including meta-analyses conducted in Western countries [6,7].…”

Section: Discussionmentioning

confidence: 91%

Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes

Maeda

Kubota

Kanamori

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 91%

Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes

Maeda

Kubota

Kanamori

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…However, it is unclear what effect the usual clinical dose of sitagliptin might have on lipid metabolism. Generally, there is no agreement about the changes of lipid parameters after administration of sitagliptin, although decreases of TC, TG and non-HDL-C have been reported in clinical studies [14-17]. …”

Section: Introductionmentioning

confidence: 99%

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus

et al. 2014

View full text Add to dashboard Cite

BackgroundAnimal studies have demonstrated that an inhibition of DPP-4 has an impact on the secretion of cholesterol and apoB by the small intestine. However, there is no consensus about the changes of the lipid profile following administration of sitagliptin.MethodsAccordingly, we treated patients who had type 2 diabetes complicated by dyslipidemia with sitagliptin and evaluated its effects on the profile of lipid parameters. A total of 248 outpatients with type 2 diabetes complicated by dyslipidemia were treated with sitagliptin at a daily dose of 50 mg. The levels and percent changes of lipid and glucose metabolism markers were measured at baseline and at 12 weeks after the initiation of treatment.ResultsBoth plasma glucose and HbA1c were significantly decreased. Among the lipid parameters, total cholesterol (TC) and non-high-density lipoprotein cholesterol (non-HDL-C) showed a significant decrease (TC 3.6±15.6%, non-HDL-C 2.9±19.7%; P < 0.05). Stratified analysis revealed a significant decrease of TC, low-density lipoprotein cholesterol (LDL-C) and non-HDL-C in the high triglyceride (TG) group (≥ 150 mg/dL) (P < 0.05). Analysis stratified by demographic factors demonstrated significant differences in the changes of TC, LDL-C and non-HDL-C. Multivariate analysis showed a significant decrease of the TC, LDL-C and non-HDL-C levels in the high TG group (≥ 150 mg/dL), as well as a significant decrease of TC and LDL-C in patients using strong statins.ConclusionsThe results suggested that sitagliptin caused a significant decrease of TC, LDL-C and non-HDL-C, particularly in patients with high baseline TG levels and those using strong statins.

show abstract

“…The DPP-4 inhibitors block the rapid inactivation of GLP-1 and improve glycaemic control [13]. It has been indicated that dipeptidyl peptidase-4 inhibitors (DPP4i) are superior to traditional oral hypoglycemic agents in terms of the efficacy and tolerability [14-17]. Such priority can be also seen from the rising status in the authoritative guideline for preventing and treating diabetes.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

Liu

Bai

et al. 2014

Diabetol Metab Syndr

View full text Add to dashboard Cite

BackgroundThe oral DPP-4 inhibitors are new incretin-based therapies for treatment of type 2 diabetes. To assess the efficacy and safety of three DPP-4 inhibitors (Saxagliptin, Sitagliptin and Vildagliptin) as add-on therapy to dual combination of traditional oral hypoglycemic agents in Chinese type 2 diabetes patients.MethodsIn this 24-week, randomized, open-label, parallel clinical trial, we enrolled inadequately controlled (glycosylated haemoglobin A1c [HbA1c] ≥7.5% to ≤10%) patients with type 2 diabetes, who were treated by dual combination of metformin and another traditional oral hypoglycemic agent (glimepiride, acarbose or pioglitazone). 207 patients had been randomized to add-on 5 mg saxagliptin group or 100 mg sitagliptin once daily group, or 50 mg vildagliptin twice daily group for 24 weeks. HbA1c, fasting and postprandial blood glucose (FBG and P2hBG), body weight, body mass index (BMI), episodes of hypoglycemia and adverse events were evaluated.ResultAfter 24 weeks, HbA1c, FBG, and P2hBG of each group were significantly decreased. (saxagliptin vs vildagliptin vs sitagliptin: HbA1c: -1.2% vs -1.3% vs -1.1%; FBG: -1.8 mmol/l vs -2.4 mmol/l vs -1.5 mmol/l; P2hBG: -3.4 mmol/l vs -3.7 mmol/l vs -3.2 mmol/l). The changes of HbA1c and P2hBG among the three groups had no significance. However, vildagliptin-added group showed the greatest reduction (p < 0.001), while, sitagliptin-added group showed the lowest reduction (p < 0.001) in terms of FPG changes. Proportions of patients achieving HbA1c < 7% at the end were similar in three groups (saxagliptin 59%, vildagliptin 65%, sitagliptin 59%). Mild hypoglycemia was commonly reported among the three groups (saxagliptin 6%, vildagliptin 2%, sitagliptin 3%). No significant between-group difference was shown in other AEs.ConclusionThe three gliptins showed almost similar glycemic control and incidence of adverse events. However, for FBG control, saxagliptin demonstrated superiority to sitagliptin, while, inferiority to vildagliptin.

show abstract

Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial

Abstract: Sitagliptin was not only more tolerable, but also more effective than pioglitazone in Japanese type 2 diabetic patients who had been treated with metformin and/or sulphonylurea.

Cited by 30 publications

References 40 publications

Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes

Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

Contact Info

Product

Resources

About